Serum-Free Medium for AAV Production

Moving AAV production from serum-containing to serum-free medium is increasingly driven by regulatory pressure — particularly for IND-enabling and clinical-grade AAV where animal-derived components require extensive TSE/BSE documentation. This post gives you the complete component list, explains what each component replaces in FBS, and provides a practical transition protocol.

Why go serum-free for AAV production?

For research-grade AAV, optimised Low Endotoxin FBS gives excellent results and the transition to serum-free adds complexity without clear benefit. For clinical-grade AAV, the calculation changes:

• Regulatory burden: FBS requires TSE/BSE risk assessment, country of origin certification, and lot-specific adventitious agent documentation — reviewed by FDA/EMA at every IND/CTA submission
• Batch-to-batch consistency: serum-free chemically defined medium has zero lot-to-lot variability in composition — eliminating FBS-driven titre variation
• Downstream processing: bovine albumin in FBS co-purifies with AAV through many purification steps and must be documented as a process-related impurity
• GMP compliance: animal component-free (ACF) medium simplifies the raw material risk assessment and removes a key regulatory concern for commercial AAV manufacturing

What FBS does — and what you need to replace

FBS provides six key functions in HEK293T medium. Each must be replaced individually in a serum-free formulation:

The complete serum-free HEK293T medium for AAV production

Starting from DMEM high glucose with L-glutamine (no pyruvate — pyruvate competes with glucose metabolism), add:

rHSA — why rice-expressed OsrhHSA is the correct choice

rHSA for AAV production medium must be animal-free and xeno-free. Three expression systems are commercially available:

• Rice-expressed OsrhHSA (Oryza sativa): fully animal-free, no mammalian cell contamination risk, ≥95% purity, used in commercial AAV GMP processes — this is the correct choice for ACF AAV medium
• Yeast-expressed rHSA (Pichia pastoris): animal-free but some batches have yeast-specific glycosylation artefacts — acceptable but less preferred for GMP
• CHO-expressed rHSA: mammalian-expressed — no longer ACF, reintroduces animal component risk

Transition protocol — FBS to serum-free in HEK293T

HEK293T cells adapt to serum-free medium more readily than most mammalian cell lines — typically 3–5 passages. The recommended transition:

1. Passage 1: DMEM + 5% FBS + full serum-free supplement package
2. Passage 2: DMEM + 2% FBS + full serum-free supplement package
3. Passage 3: DMEM + 1% FBS + full serum-free supplement package
4. Passage 4: DMEM + serum-free supplements only — no FBS
5. Passage 5+: Run a small-scale AAV production test to confirm titre equivalence before committing to full-scale serum-free production

Monitor doubling time at each passage — acceptable doubling time in serum-free DMEM for HEK293T is ≤22 hours. If doubling time exceeds 24 hours at any step, hold at that FBS concentration for one additional passage before reducing further.

What titre to expect from serum-free vs. FBS-containing medium

With a well-optimised serum-free formulation, AAV titres in serum-free medium are equivalent to optimised Low Endotoxin FBS — and in some labs slightly higher, because the absence of endotoxin and variable growth factor composition removes sources of batch-to-batch variability. Expect a 1–2 passage adaptation period where titres may be 30–50% below FBS baseline before recovering to equivalent or higher levels.